Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients

被引：1
|
作者：
不详
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-151161
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1616
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment
    Kosei Matsue
    Kazutaka Sunami
    Morio Matsumoto
    Junya Kuroda
    Isamu Sugiura
    Hiromi Iwasaki
    Weiyuan Chung
    Shigeki Kuwayama
    Mitsufumi Nishio
    Kim Lee
    Shinsuke Iida
    International Journal of Hematology, 2022, 116 : 122 - 130
  • [32] Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Bahlis, Nizar
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea C.
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    Leblanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie Scott
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2019, 134
  • [33] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
    Lentzsch, Suzanne
    Quach, Hang
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Thiyagarajah, Piruntha
    Amin, Himal
    Casneuf, Tineke
    Sonneveld, Pieter
    Schecter, Jordan
    Hungria, Vania T. M.
    BLOOD, 2017, 130
  • [34] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Ahmadi, Tahamtan
    Ukropec, Jon
    Kampfenkel, Tobias
    Schecter, Jordan
    Qiu, Yanping
    Amin, Himal
    Vermeulen, Jessica
    Carson, Robin
    Sonneveld, Pieter
    BLOOD, 2020, 136
  • [35] Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Ray
    Wang, Jim
    Masterson, Tara
    Nottage, Kerri
    Schecter, Jordan
    Chiu, Christopher
    Khokhar, Nushmia
    Ahmadi, Tahamtan
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E14 - E15
  • [36] Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    He, Jianming
    Berringer, Heather
    Heeg, Bart
    Kampfenkel, Tobias
    Dwarakanathan, Harikumaran R.
    Johnston, Stephen
    Mendes, Joao
    Lam, Annette
    Bathija, Sacheeta
    Mackay, Eric
    BLOOD, 2021, 138
  • [37] Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary J.
    Callander, Natalie Scott
    Tuchman, Sascha
    Bahlis, Nizar J.
    White, Darrell
    Chen, Christine
    Baljevic, Muhamed
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Bensinger, William
    Rossi, Adriana C.
    Sheehan, Heidi
    Arazy, Melina
    Kai, Kazuharu
    Lipe, Brea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
  • [39] A phase I/II study of Pomalidomide, Ixazomib, Clarithromycin and Dexamethasone (PICd) in patients with relapsed or refractory Multiple Myeloma (RRMM)
    Rosenberg, Aaron
    Munoz, Meilen
    Costello, Caitlin
    Brem, Elizabeth
    Reid, Erin
    Maverakis, Emanual
    Kaesberg, Paul
    Lee, Lisa
    Abedi, Mehrdad
    Tuscano, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S157 - S158
  • [40] HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Rodriguez Otero, Paula
    Norkin, Maxim
    Blade, Joan
    Cavo, Michele
    Hassoun, Hani
    Leleu, Xavier
    Alegre, Adrian
    Maisel, Christopher
    Paner, Agne
    Mazumder, Amitabha
    Zonder, Jeffrey A.
    Puig, Noemi
    Harran, John
    Harmenberg, Johan
    Thuresson, Sara
    Zubair, Hanan
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S329 - S330
12345